Latham & Watkins Advises on Immunovant’s US$75 Million Underwritten Offering of Common Stock
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, has announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at an offering price of US$6.00 per share. Before deducting the underwriting discounts and commissions and offering expenses, the company expects to receive total gross proceeds of US$75.0 million. All of the shares are to be sold by the company. The offering is expected to close on or about October 6, 2022, subject to satisfaction of customary closing conditions.
Latham & Watkins LLP represents the underwriters in the offering with a corporate deal team led by New York partner Nathan Ajiashvili, with associates Kaj Nielsen, Egzon Sulejmani, and Jie Lin Nai.